Review
doi: 10.1111/j.1440-1746.2005.04167.x.
CYP2C19 genotype and the PPIs--focus on rabeprazole
Affiliations
- PMID: 16359346
- DOI: 10.1111/j.1440-1746.2005.04167.x
Item in Clipboard
Review
CYP2C19 genotype and the PPIs--focus on rabeprazole
J Gastroenterol Hepatol.
2005 Dec.
Abstract
Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders.
Similar articles
-
Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S20-1. doi: 10.1111/j.1440-1746.2005.04179.x. J Gastroenterol Hepatol. 2005. PMID: 16359345 Review. No abstract available.
-
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.Aliment Pharmacol Ther. 2004 Nov;20 Suppl 6:11-9. doi: 10.1111/j.1365-2036.2004.02161.x. Aliment Pharmacol Ther. 2004. PMID: 15496214 Review.
-
Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S61-8. doi: 10.1111/j.1440-1746.2004.03592.x. J Gastroenterol Hepatol. 2004. PMID: 15324384 Review.
-
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.J Gastroenterol Hepatol. 2002 Jul;17(7):748-53. doi: 10.1046/j.1440-1746.2002.02790.x. J Gastroenterol Hepatol. 2002. PMID: 12121503 Clinical Trial.
-
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.Aliment Pharmacol Ther. 2001 Sep;15(9):1479-84. doi: 10.1046/j.1365-2036.2001.01063.x. Aliment Pharmacol Ther. 2001. PMID: 11552922 Clinical Trial.
Cited by
-
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Clin Drug Investig. 2017 Jul;37(7):587-624. doi: 10.1007/s40261-017-0519-y. Clin Drug Investig. 2017. PMID: 28361440 Review.
-
Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.J Gastroenterol. 2011 Jul;46(7):906-12. doi: 10.1007/s00535-011-0402-1. Epub 2011 May 3. J Gastroenterol. 2011. PMID: 21538030 Clinical Trial.
-
Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea.Gut Liver. 2017 Jul 15;11(4):504-511. doi: 10.5009/gnl16352. Gut Liver. 2017. PMID: 28395507 Free PMC article. Clinical Trial.
-
CYP2C19 variability and clinical outcomes of clopidogrel, proton pump inhibitors, and voriconazole in Southeast Asia: a systematic review and meta-analysis.Front Pharmacol. 2025 Jun 19;16:1572886. doi: 10.3389/fphar.2025.1572886. eCollection 2025. Front Pharmacol. 2025. PMID: 40612749 Free PMC article.
-
Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?Clin Pharmacokinet. 2008;47(1):1-6. doi: 10.2165/00003088-200847010-00001. Clin Pharmacokinet. 2008. PMID: 18076214 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
